<DOC>
	<DOCNO>NCT00910858</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetic pharmacodynamic characteristic oral lenalidomide monotherapy administer patient Low- Intermediate-1-risk Myelodysplastic Syndrome ( MDS ) .</brief_summary>
	<brief_title>A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide ( Revlimid ) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Must understand voluntarily sign informed consent form . 2 . Age ≥18 year time signing informed consent form . 3 . Must able adhere study visit schedule protocol requirement . 4 . Documented diagnosis MDS meet International Prognostic Scoring System ( IPSS ) criteria Low Intermediate1risk disease . •Must diagnosis low intermediate risk MDS without del 5q chromosomal abnormality ( patient take 15 mg start dose ) . 5 . Must able provide adequate bone marrow ( BM ) aspirate biopsy specimen histopathological analysis standard cytogenetic analysis screen procedure . 6 . Red blood cell ( RBC ) transfusiondependent anemia define receive ≥4 transfusion RBCs within 56 day randomization symptomatic anemia ( hemoglobin &lt; 9.0 g/dl ) . 7 . Failed prior treatment recombinant human erythropoietin ( rhuEPO ) ( ≥ 30,000 U/week x 6 ) serum erythropoietin ( EPO ) concentration ≥500 mU/ml ( hemoglobin &lt; 9.0 g/dl ) . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . 9 . Females childbearing potential ( FCBP ) must agree use two reliable form contraception simultaneously practice complete abstinence heterosexual intercourse 1 ) least 28 day start study drug ; 2 ) participate study ; 3 ) least 28 day discontinuation study . The two method reliable contraception must include one highly effective method ( i.e . intrauterine device [ IUD ] , hormonal [ birth control pill , injection , implant ] , tubal ligation , partner 's vasectomy ) one additional effective ( barrier ) method ( i.e . latex condom , diaphragm , cervical cap ) . FCBP must refer qualified provider contraceptive method , need . 1 . Pregnant lactating female . 2 . Prior therapy lenalidomide . 3 . Proliferative white blood cell ( WBC ) ≥12,000/µL ) chronic myelomonocytic leukemia ( CMML ) . 4 . MDS secondary treatment radiotherapy , chemotherapy , and/or immunotherapy malignant autoimmune disease . 5 . Any following lab abnormality : Absolute neutrophil count ( ANC ) &lt; 500 cells/µL ( 0.5 x 10^9/L ) Platelet count &lt; 50,000/µL ( 50 x 10^9/L ) Serum creatinine &gt; upper limit normal ( ULN ) Serum glutamic oxaloacetic transaminase/aspartate transaminase ( SGOT/AST ) serum glutamic pyruvic transaminase/alanine transaminase ( SGPT/ALT ) &gt; 2.0 x ULN Serum total bilirubin &gt; 2.0 mg/dL ( 34 µmol/L ) 6 . Prior ≥grade2 National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) allergic reaction thalidomide . 7 . Prior desquamating ( blister ) rash take thalidomide . 8 . Patients ≥grade2 neuropathy . 9 . Clinically significant anemia due factor iron , B12 folate deficiency , autoimmune hereditary hemolysis gastrointestinal bleeding . 10 . Use cytotoxic chemotherapeutic agent , erythropoietin , experimental agent ( agent commercially available ) treatment MDS within 28 day first day study drug treatment . 11 . Prior history malignancy MDS ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease ≥3 year . 12 . Any serious medical condition psychiatric illness prevent patient signing informed consent form place subject unacceptable risk he/she participate study . 13 . Known human immunodeficiency virus ( HIV1 ) positivity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>